Pfizer Lung Cancer Drug Fails; FDA Speeds Trial Pilot
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pfizer disclosed that its experimental lung cancer drug sigvotatug vedotin failed to deliver a statistically significant overall survival improvement over docetaxel, a chemotherapy first approved in 1996, in a late-stage clinical trial.
- Pfizer obtained sigvotatug vedotin through its $43 billion acquisition of Seagen in 2023, and CEO Albert Bourla told investors on an earnings call last year the drug "could be a driver of growth later this decade."
- The FDA announced a pilot program to speed early-stage clinical trials, projecting it will cut development timelines by six to 12 months and help counter Chinese dominance in early-stage research.
- Acting FDA Commissioner Kyle Diamantas said the agency will issue guidance reaffirming that a single high-quality Phase 3 trial backed by confirmatory evidence is sufficient for drug approval.
- The FDA is using the president's 2027 fiscal budget request to ask Congress to establish a permanent faster process for the existing Investigational New Drug pathway.
- The pilot is framed as a way to encourage drugmakers to run more trials in the U.S. rather than abroad.
Why it matters: Pfizer's $43 billion Seagen bet just lost its clearest growth narrative — CEO Bourla's public claim that sigvotatug vedotin could drive revenue later this decade no longer holds up after the trial miss. On the regulatory side, the FDA is pushing a two-pronged reform (pilot program plus a permanent IND pathway ask to Congress) that could materially shorten U.S. drug development timelines by up to a year.
Ask SkimNews
